Large-Scale Predictive Drug Safety: From Structural Alerts to Biological Mechanisms

Chemical Research in Toxicology

Volumn 28, Issue 10, 2015, Pages 1875-1887

  Garcia Serna, Ricard ^a   Vidal, David ^a   Remez, Nikita ^a,b   Mestres, Jordi ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE OUTCOME; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; COMPUTER MODEL; DRUG CLASSIFICATION; DRUG MONITORING; DRUG SAFETY; DRUG STRUCTURE; HUMAN; IN VITRO STUDY; NONHUMAN; POLYPHARMACOLOGY; RISK ASSESSMENT; ADVERSE DRUG REACTION; FACTUAL DATABASE; METABOLISM;

DRUG;

DATABASES, FACTUAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; METABOLIC NETWORKS AND PATHWAYS; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT;

EID: 84944729372     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/acs.chemrestox.5b00260     Document Type: Article

References (141)

1. Arrowsmith, J. and Miller, P. (2013) Trial watch: phase II and phase III attrition rates 2011-2012 Nat. Rev. Drug Discovery 12, 569 10.1038/nrd4090
2. Arrowsmith, J. (2011) Trial watch: phase II failure 2008-2010 Nat. Rev. Drug Discovery 10, 328-329 10.1038/nrd3439
3. Furberg, C. D. and Pitt, B. (2001) Withdrawal of cerivastatin from the world market Curr. Control Trials Cardiovasc. Med. 2, 205-207 10.1186/CVM-2-5-205
4. EU-ADR project. http://www.euadr-project.org (accessed March 20, 2015).
5. Oliveira, J. L., Lopes, P., Nunes, T., Campos, D., Boyer, S., Ahlberg, E., van Mulligen, E. M., Kors, J. A., Singh, B., Furlong, L. I., Sanz, F., Bauer-Mehren, A., Carrascosa, M. C., Mestres, J., Avillach, P., Diallo, G., Díaz Acedo, C., and van der Lei, J. (2013) The EU-ADR web platform: delivering advanced pharmacovigilance tools Pharmacoepidemiol. Drug Saf. 22, 459-467 10.1002/pds.3375
6. Giacomini, K. M., Krauss, R. M., Roden, D. M., Eichelbaum, M., Hayden, M. R., and Nakamura, Y. (2007) When good drugs go bad Nature 446, 975-977 10.1038/446975a
7. eTOX project. http://www.etoxproject.eu (accessed March 20, 2015).
8. Arrowsmith, J. (2011) Trial watch: phase III and submission failures 2007-2010 Nat. Rev. Drug Discovery 10, 87 10.1038/nrd3375
9. Cases, M., Briggs, K., Steger-Hartmann, T., Pognan, F., Marc, P., Kleinöder, T., Schwab, C. H., Pastor, M., Wichard, J., and Sanz, F. (2014) The eTOX data-sharing project to advance in silico drug-induced toxicity prediction Int. J. Mol. Sci. 15, 21136-21154 10.3390/ijms151121136
10. Briggs, K., Cases, M., Heard, D. J., Pastor, M., Pognan, F., Sanz, F., Schwab, C. H., Steger-Hartmann, T., Sutter, A., Watson, D. K., and Wichard, J. D. (2012) Inroads to predict in vivo toxicology-an introduction to the eTOX project Int. J. Mol. Sci. 13, 3820-3846 10.3390/ijms13033820
11. Mestres, J., Bryant, S. D., Zamora, I., and Gasteiger, J. (2011) Shaping the future of safer innovative drugs in Europe Nat. Biotechnol. 29, 789-790 10.1038/nbt.1973
12. ToxCast project. http://www.epa.gov/ncct/toxcast (accessed March 20, 2015).
13. Tox21 platform. http://epa.gov/ncct/Tox21 (accessed March 20, 2015).
14. Kleinstreuer, N. C., Yang, J., Berg, E. L., Knudsen, T. B., Richard, A. M., Martin, M. T., Reif, D. M., Judson, R. S., Polokoff, M., Dix, D. J., Kavlock, R. J., and Houck, K. A. (2014) Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms Nat. Biotechnol. 32, 583-591 10.1038/nbt.2914
15. Attene-Ramos, M. S., Miller, N., Huang, R., Michael, S., Itkin, M., Kavlock, R. J., Austin, C. P., Shinn, P., Simeonov, A., Tice, R. R., and Xia, M. (2013) The Tox21 robotic platform for the assessment of environmental chemicals-from vision to reality Drug Discovery Today 18, 716-723 10.1016/j.drudis.2013.05.015
16. Open TG-GATEs. http://toxico.nibio.go.jp/english/index.html (accessed March 20, 2015).
17. Igarashi, Y., Nakatsu, N., Yamashita, T., Ono, A., Ohno, Y., Urushidani, T., and Yamada, H. (2015) Open TG-GATEs: a large-scale toxicogenomics database Nucleic Acids Res. 43, D921-D927 10.1093/nar/gku955
18. Williams, D. P. (2006) Toxicophores: investigations in drug safety Toxicology 226, 1-11 10.1016/j.tox.2006.05.101
19. Ahlberg, E., Carlsson, L., and Boyer, S. (2014) Computational derivation of structural alerts from large toxicology data sets J. Chem. Inf. Model. 54, 2945-2952 10.1021/ci500314a
20. Gaulton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B., and Overington, J. P. (2012) ChEMBL: a large-scale bioactivity database for drug discovery Nucleic Acids Res. 40, D1100-D1107 10.1093/nar/gkr777
21. Williams, A. J., Ekins, S., Spjuth, O., and Willighagen, E. L. (2012) Accessing, using, and creating chemical property databases for computational toxicology modeling Methods Mol. Biol. 929, 221-241 10.1007/978-1-62703-050-2-10
22. Williams, A. J., Harland, L., Groth, P., Pettifer, S., Chichester, C., Willighagen, E. L., Evelo, C. T., Blomberg, N., Ecker, G., Goble, C., and Mons, B. (2012) Open PHACTS: semantic interoperability for drug discovery Drug Discovery Today 17, 1188-1198 10.1016/j.drudis.2012.05.016
23. Bouhifd, M., Andersen, M. E., Baghdikian, C., Boekelheide, K., Crofton, K. M., Fornace, A. J., Jr., Kleensang, A., Li, H., Livi, C., Maertens, A., McMullen, P. D., Rosenberg, M., Thomas, R., Vantangoli, M., Yager, J. D., Zhao, L., and Hartung, T. (2015) The human toxome project ALTEX 32, 112-124 10.14573/altex.1502091
24. Tollefsen, K. E., Scholz, S., Cronin, M. T., Edwards, S. W., de Knecht, J., Crofton, K., Garcia-Reyero, N., Hartung, T., Worth, A., and Patlewicz, G. (2014) Applying adverse outcome pathways (AOPs) to support integrated approaches to testing and assessment (IATA) Regul. Toxicol. Pharmacol. 70, 629-640 10.1016/j.yrtph.2014.09.009
25. Chiang, A. P. and Butte, A. J. (2009) Data-driven methods to discover molecular determinants of serious adverse drug events Clin. Pharmacol. Ther. 85, 259-268 10.1038/clpt.2008.274
26. Pouliot, Y., Chiang, A. P., and Butte, A. J. (2011) Predicting adverse drug reactions using publicly available PubChem BioAssay data Clin. Pharmacol. Ther. 90, 90-99 10.1038/clpt.2011.81
27. Nigsch, F., Lounkine, E., McCarren, P., Cornett, B., Glick, M., Azzaoui, K., Urban, L., Marc, P., Müller, A., Hahne, F., Heard, D. J., and Jenkins, J. L. (2011) Computational methods for early predictive safety assessment from biological and chemical data Expert Opin. Drug Metab. Toxicol. 7, 1497-1511 10.1517/17425255.2011.632632
28. Lee, S., Lee, K. H., Song, M., and Lee, D. (2011) Building the process-drug-side effect network to discover the relationship between biological processes and side effects BMC Bioinf. 12, S2 10.1186/1471-2105-12-S2-S2
29. Bauer-Mehren, A., van Mullingen, E. M., Avillach, P., Carrascosa, M. C., Garcia-Serna, R., Piñero, J., Singh, B., Lopes, P., Oliveira, J. L., Diallo, G., Ahlberg Helgee, E., Boyer, S., Mestres, J., Sanz, F., Kors, J. A., and Furlong, L. I. (2012) Automatic filtering and substantiation of drug safety signals PLoS Comput. Biol. 8, e1002457 10.1371/journal.pcbi.1002457
30. Declerck, G., Hussain, S., Daniel, C., Yuksel, M., Laleci, G. B., Twagirumukiza, M., and Jaulent, M. C. (2015) Bridging data models and terminologies to support adverse drug event reporting using EHR data Methods Inf. Med. 54, 24-31 10.3414/ME13-02-0025
31. Liu, M., Hu, Y., and Tang, B. (2014) Role of text mining in early identification of potential drug safety issues Methods Mol. Biol. 1159, 227-251 10.1007/978-1-4939-0709-0-13
32. White, R. W., Tatonetti, N. P., Shah, N. H., Altman, R. B., and Horvitz, E. (2013) Web-scale pharmacovigilance: listening to signals from the crowd J. Am. Med. Inform. Assoc. 20, 404-408 10.1136/amiajnl-2012-001482
33. Freifeld, C. C., Brownstein, J. S., Menone, C. M., Bao, W., Filice, R., Kass-Hout, T., and Dasgupta, N. (2014) Digital drug safety surveillance: monitoring pharmaceutical products in twitter Drug Saf. 37, 343-350 10.1007/s40264-014-0155-x
34. Bousquet, C., Sadou, é., Souvignet, J., Jaulent, M. C., and Declerck, G. (2014) Formalizing MedDRA to support semantic reasoning on adverse drug reaction terms J. Biomed. Inf. 49, 282-291 10.1016/j.jbi.2014.03.012
35. Cai, M. C., Xu, Q., Pan, Y. J., Pan, W., Ji, N., Li, Y. B., Jin, H. J., Liu, K., and Ji, Z. L. (2015) ADReCS: an ontology database for aiding standardization and hierarchical classification of adverse drug reaction terms Nucleic Acids Res. 43, D907-D913 10.1093/nar/gku1066
36. Strauss, A., Lawrence Gould, A., Nelsen, L. M., Wiholm, B. E., and Jones, J. K. (2005) Public-released version of the Adverse Event Reporting System (AERS) database Clin. Ther. 27, 355-357 10.1016/S0149-2918(05)00053-6
37. Tatonetti, N. P., Ye, P. P., Daneshjou, R., and Altman, R. B. (2012) Data-driven prediction of drug effects and interactions Sci. Transl. Med. 4, 125ra31 10.1126/scitranslmed.3003377
38. Vlug, A. E., van der Lei, J., Mosseveld, B. M., van Wijk, M. A., van der Linden, P. D., Sturkenboom, M. C., and van Bemmel, J. H. (1999) Postmarketing surveillance based on electronic patient records: the IPCI project Methods Inf. Med. 38, 339-344
39. Kuhn, M., Campillos, M., Letunic, I., Jensen, L. J., and Bork, P. (2010) A side effect resource to capture phenotypic effects of drugs Mol. Syst. Biol. 6, 343 10.1038/msb.2009.98
40. Brown, E. G., Wood, L., and Wood, S. (1999) The medical dictionary for regulatory activities (MedDRA) Drug Saf. 20, 109-117 10.2165/00002018-199920020-00002
41. World Drug Index. http://thomsonreuters.com/world-drug-index (accessed March 20, 2015).
42. Pharmapendium. http://www.elsevier.com/online-tools/pharmapendium (accessed March 20, 2015).
43. Toxicity Reference Database. http://actor.epa.gov/toxrefdb (accessed March 20, 2015).
44. DrugMatrix. http://ntp.niehs.nih.gov/drugmatrix/index.html (accessed March 20, 2015).
45. Mestres, J., Gregori-Puigjané, E., Valverde, S., and Solé, R. V. (2008) Data completeness: the Achilles heel of drug-target networks Nat. Biotechnol. 26, 983-984 10.1038/nbt0908-983
46. Mestres, J., Gregori-Puigjané, E., Valverde, S., and Solé, R. V. (2009) The topology of drug-target interaction networks: implicit dependence on drug properties and target families Mol. BioSyst. 5, 1051-1057 10.1039/b905821b
47. Vogt, I. and Mestres, J. (2010) Drug-target networks Mol. Inf. 29, 10-14 10.1002/minf.200900069
48. Peters, J. U. (2013) Polypharmacology: foe or friend? J. Med. Chem. 56, 8955-8971 10.1021/jm400856t
49. Jalencas, X. and Mestres, J. (2013) On the origins of drug polypharmacology MedChemComm 4, 80-87 10.1039/C2MD20242E
50. Anighoro, A., Bajorath, J., and Rastelli, G. (2014) Polypharmacology: challenges and opportunities in drug discovery J. Med. Chem. 57, 7874-7887 10.1021/jm5006463
51. Whitebread, S., Hamon, J., Bojanic, D., and Urban, L. (2005) In vitro safety pharmacology profiling: an essential tool for successful drug development Drug Discovery Today 10, 1421-1433 10.1016/S1359-6446(05)03632-9
52. Bender, A., Scheiber, J., Glick, M., Davies, J. W., Azzaoui, K., Hamon, J., Urban, L., Whitebread, S., and Jenkins, J. L. (2007) Analysis of pharmacology data and the prediction of adverse drug reaction and off-target effects from chemical structure ChemMedChem 2, 861-873 10.1002/cmdc.200700026
53. Hamon, J., Whitebread, S., Techer-Etienne, V., Le Coq, H., Azzaoui, K., and Urban, L. (2009) In vitro safety pharmacology profiling: what else beyond hERG? Future Med. Chem. 1, 645-665 10.4155/fmc.09.51
54. Garcia-Serna, R. and Mestres, J. (2010) Anticipating drug side effects by comparative pharmacology Expert Opin. Drug Metab. Toxicol. 6, 1253-1263 10.1517/17425255.2010.509343
55. Mestres, J., Seifert, S. A., and Oprea, T. I. (2011) Linking pharmacology to clinical reports: cyclobenzaprine and its possible association with serotonin syndrome Clin. Pharmacol. Ther. 90, 662-665 10.1038/clpt.2011.177
56. Lounkine, E., Keiser, M. J., Whitebread, S., Mikhailov, D., Hamon, J., Jenkins, J. L., Lavan, P., Weber, E., Doak, A. K., Coîté, S., Shoichet, B. K., and Urban, L. (2012) Large-scale prediction and testing of drug activity on side-effect targets Nature 486, 361-367 10.1038/nature11159
57. Evans, W. E. and McLeod, H. L. (2003) Pharmacogenomics-drug disposition, drug targets, and side effects N. Engl. J. Med. 348, 538-549 10.1056/NEJMra020526
58. Rieder, M. J. (1993) Immunopharmacology and adverse drug reactions J. Clin. Pharmacol. 33, 316-323 10.1002/j.1552-4604.1993.tb04663.x
59. Park, B. K., Kitteringham, N. R., Maggs, J. L., Pirmohamed, M., and Williams, D. P. (2005) The role of metabolic activation in drug-induced hepatotoxicity Annu. Rev. Pharmacol. Toxicol. 45, 177-202 10.1146/annurev.pharmtox.45.120403.100058
60. Uetrecht, J. (2008) Idiosyncratic drug reactions: past, present, and future Chem. Res. Toxicol. 21, 84-92 10.1021/tx700186p
61. Uetrecht, J. and Naisbitt, D. J. (2013) Idiosyncratic adverse drug reactions: current concepts Pharmacol. Rev. 65, 779-808 10.1124/pr.113.007450
62. Wang, Y., Suzek, T., Zhang, J., Wang, J., He, S., Cheng, T., Shoemaker, B. A., Gindulyte, A., and Bryant, S. H. (2014) PubChem BioAssay: 2014 update Nucleic Acids Res. 42, D1075-D1082 10.1093/nar/gkt978
63. Bento, A. P., Gaulton, A., Hersey, A., Bellis, L. J., Chambers, J., Davies, M., Krüger, F. A., Light, Y., Mak, L., McGlinchey, S., Nowotka, M., Papadatos, G., Santos, R., and Overington, J. P. (2014) The ChEMBL bioactivity database: an update Nucleic Acids Res. 42, D1083-D1090 10.1093/nar/gkt1031
64. Hu, Y. and Bajorath, J. (2012) Extending the activity cliff concept: structural categorization of activity cliffs and systematic identification of different types of cliffs in the ChEMBL database J. Chem. Inf. Model. 52, 1806-1811 10.1021/ci300274c
65. Liu, T., Lin, Y., Wen, X., Jorissen, R. N., and Gilson, M. K. (2007) BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities Nucleic Acids Res. 35, D198-D201 10.1093/nar/gkl999
66. Wassermann, A. M. and Bajorath, J. (2011) BindingDB and ChEMBL: online compound databases for drug discovery Expert Opin. Drug Discovery 6, 683-687 10.1517/17460441.2011.579100
67. Law, V., Knox, C., Djoumbou, Y., Jewison, T., Guo, A. C., Liu, Y., Maciejewski, A., Arndt, D., Wilson, M., Neveu, V., Tang, A., Gabriel, G., Ly, C., Adamjee, S., Dame, Z. T., Han, B., Zhou, Y., and Wishart, D. S. (2014) DrugBank 4.0: shedding new light on drug metabolism Nucleic Acids Res. 42, D1091-D1097 10.1093/nar/gkt1068
68. Harmar, A. J., Hills, R. A., Rosser, E. M., Jones, M., Buneman, O. P., Dunbar, D. R., Greenhill, S. D., Hale, V. A., Sharman, J. L., Bonner, T. I., Catterall, W. A., Davenport, A. P., Delagrange, P., Dollery, C. T., Foord, S. M., Gutman, G. A., Laudet, V., Neubig, R. R., Ohlstein, E. H., Olsen, R. W., Peters, J., Pin, J. P., Ruffolo, R. R., Searls, D. B., Wright, M. W., and Spedding, M. (2009) IUPHAR-DB: the IUPHAR database of G protein-couple receptors and ion channels Nucleic Acids Res. 37, D680-D685 10.1093/nar/gkn728
69. Davis, A. P., Grondin, C. J., Lennon-Hopkins, K., Saraceni-Richards, C., Sciaky, D., King, B. L., Wiegers, T. C., and Mattingly, C. J. (2015) The Comparative Toxicogenomics Database's 10th year anniversary: update 2015 Nucleic Acids Res. 43, D914-D920 10.1093/nar/gku935
70. PDSP: National Institute of Mental Health′s Psychoactive Drug Screening Program. http://pdspdb.unc.edu (accessed March 20, 2015).
71. Grover, M. P., Ballouz, S., Mohanasundaram, K. A., George, R. A., Sherman, C. D. H., Crowley, T. M., and Wouters, M. A. (2014) Identification of novel therapeutics for complex diseases from genome-wide association data BMC Med. Genomics 7 (S1) S8 10.1186/1755-8794-7-S1-S8
72. Woo, J. H., Shimoni, Y., Yang, W. S., Subramaniam, P., Iyer, A., Nicoletti, P., Rodríguez-Martínez, M., López, G., Mattioli, M., Realubit, R., Karan, C., Stockwell, B. R., Bansal, M., and Califano, A. (2015) Elucidating compound mechanism of action by network perturbation analysis Cell 162, 441-451 10.1016/j.cell.2015.05.056
73. Vinken, M., Whelan, M., and Rogiers, V. (2014) Adverse outcome pathways: hype or hope? Arch. Toxicol. 88, 1-2 10.1007/s00204-013-1093-6
74. Croft, D., Mundo, A. F., Haw, R., Milacic, M., Weiser, J., Wu, G., Caudy, M., Garapati, P., Gillespie, M., Kamdar, M. R., Jassal, B., Jupe, S., Matthews, L., May, B., Palatnik, S., Rothfels, K., Shamovsky, V., Song, H., Williams, M., Birney, E., Hermjakob, H., Stein, L., and D'Eustachio, P. (2014) The Reactome pathway knowledgebase Nucleic Acids Res. 42, D472-D477 10.1093/nar/gkt1102
75. Cerami, E. G., Gross, B. E., Demir, E., Rodchenkov, I., Babur, O., Anwar, N., Schultz, N., Bader, G. D., and Sander, C. (2011) Pathway Commons, a web resource for biological pathway data Nucleic Acids Res. 39, D685-D690 10.1093/nar/gkq1039
76. Kelder, T., van Iersel, M. P., Hanspers, K., Kutmon, M., Conklin, B. R., Evelo, C. T., and Pico, A. R. (2012) WikiPathways: building research communities on biological pathways Nucleic Acids Res. 40, D1301-D1307 10.1093/nar/gkr1074
77. Whirl-Carrillo, M., McDonagh, E. M., Hebert, J. M., Gong, L., Sangkuhl, K., Thorn, C. F., Altman, R. B., and Klein, T. E. (2012) Pharmacogenomics knowledge for personalized medicine Clin. Pharmacol. Ther. 92, 414-417 10.1038/clpt.2012.96
78. Qin, C., Zhang, C., Zhu, F., Xu, F., Chen, S. Y., Zhang, P., Li, Y. H., Yang, S. Y., Wei, Y. Q., Tao, L., and Chen, Y. Z. (2014) Therapeutic target database update 2014: a resource for targeted therapeutics Nucleic Acids Res. 42, D1118-D1123 10.1093/nar/gkt1129
79. AOP-KB. http://aopkb.org (accessed March 20, 2015).
80. Kotera, M., Hirakawa, M., Tokimatsu, T., Goto, S., and Kanehisa, M. (2012) The KEGG databases and tools facilitating omics analysis: latest developments involving human diseases and pharmaceuticals Methods Mol. Biol. 802, 19-39 10.1007/978-1-61779-400-1-2
81. Kuhn, M., Al Banchaabouchi, M., Campillos, M., Jensen, L. J., Gross, C., Gavin, A. C., and Bork, P. (2013) Systematic identification of proteins that elicit drug side effects Mol. Syst. Biol. 9, 663 10.1038/msb.2013.10
82. Shepherd, G. (2006) Treatment of poisoning caused by beta-adrenergic and calcium-channel blockers Am. J. Health-Syst. Pharm. 63, 1828-1835 10.2146/ajhp060041
83. Ahmed, R. and Branley, H. M. (2009) Reversible bronchospasm with the cardio-selective beta-blocker celiprolol in a non-asthmatic subject Respir. Med. CME 2, 141-143 10.1016/j.rmedc.2008.10.019
84. Rampe, D. and Brown, A. M. (2013) A history of the role of the hERG channel in cardiac risk assessment J. Pharmacol. Toxicol. Methods 68, 13-22 10.1016/j.vascn.2013.03.005
85. Roth, B. L. (2007) Drugs and valvular heart disease N. Engl. J. Med. 356, 6-9 10.1056/NEJMp068265
86. Davies, M., Dedman, N., Hersey, A., Papadatos, G., Hall, M. D., Cucurull-Sanchez, L., Jeffrey, P., Hasan, S., Eddershaw, P. J., and Overington, J. P. (2015) ADME SARfari: comparative genomics of drug metabolizing systems Bioinformatics 31, 1695-1697 10.1093/bioinformatics/btv010
87. Briansó, F., Carrascosa, M. C., Oprea, T. I., and Mestres, J. (2011) Cross-pharmacology of G protein-coupled receptors Curr. Top. Med. Chem. 11, 1956-1963 10.2174/156802611796391285
88. Kirchmair, J., Williamson, M. J., Tyzack, J. D., Tan, L., Bond, P. J., Bender, A., and Glen, R. C. (2012) Computational prediction of metabolism: sites, products, SAR, P450 enzyme dynamics, and mechanisms J. Chem. Inf. Model. 52, 617-648 10.1021/ci200542m
89. Piechota, P., Cronin, M. T. D., Hewitt, M., and Madden, J. C. (2013) Pragmatic approaches to using computational methods to predict xenobiotic metabolism J. Chem. Inf. Model. 53, 1282-1293 10.1021/ci400050v
90. Kirchmair, J., Göller, A. H., Lang, D., Kunze, J., Testa, B., Wilson, I. D., Glen, R. C., and Schneider, G. (2015) Predicting drug metabolism: experiment and/or computation? Nat. Rev. Drug Discovery 14, 387-404 10.1038/nrd4581
91. Williams, D. P. and Park, B. K. (2003) Idiosyncratic toxicity: the role of toxicophores and bioactivation Drug Discovery Today 8, 1044-1050 10.1016/S1359-6446(03)02888-5
92. Kazius, J., McGuire, R., and Bursi, R. (2005) Derivation and validation of toxicophores for mutagenicity prediction J. Med. Chem. 48, 312-320 10.1021/jm040835a
93. Kalgutkar, A. S., Fate, G., Didiuk, M. T., and Bauman, J. (2008) Toxicophores, reactive metabolites and drug safety: when is it a cause for concern? Expert Rev. Clin. Pharmacol. 1, 515-531 10.1586/17512433.1.4.515
94. Scheiber, J., Jenkins, J. L., Sukuru, S. C., Bender, A., Mikhailov, D., Milik, M., Azzaoui, K., Whitebread, S., Hamon, J., Urban, L., Glick, M., and Davies, J. W. (2009) Mapping adverse drug reactions in chemical space J. Med. Chem. 52, 3103-3107 10.1021/jm801546k
95. Ellison, C. M., Enoch, S. J., and Cronin, M. T. D. (2011) A review of the use of in silico methods to predict the chemistry of molecular initiating events related to drug toxicity Expert Opin. Drug Metab. Toxicol. 7, 1481-1495 10.1517/17425255.2011.629186
96. Przybylak, K. R. and Cronin, M. T. D. (2011) In silico studies of the relationship between chemical structure and drug induced phospholipidosis Mol. Inf. 30, 415-429 10.1002/minf.201000164
97. Sullivan, K. M., Manuppello, J. R., and Willett, C. E. (2014) Building on a solid foundation: SAR and QSAR as a fundamental strategy to reduce animal testing SAR QSAR Environ. Res. 25, 357-365 10.1080/1062936X.2014.907203
98. Bhatia, S., Schultz, T., Roberts, D., Shen, J., Kromidas, L., and Marie Api, A. (2015) Comparison of Cramer classification between ToxTree, the OECD QSAR Toolbox and expert judgment Regul. Toxicol. Pharmacol. 71, 52-62 10.1016/j.yrtph.2014.11.005
99. Patlewicz, G., Jeliazkova, N., Safford, R. J., Worth, A. P., and Aleksiev, B. (2008) An evaluation of the implementation of the Cramer classification scheme in the Toxtree software SAR QSAR Environ. Res. 19, 495-524 10.1080/10629360802083871
100. Hardy, B., Douglas, N., Helma, C., Rautenberg, M., Jeliazkova, N., Jeliazkov, V., Nikolova, I., Benigni, R., Tcheremenskaia, O., Kramer, S., Girschick, T., Buchwald, F., Wicker, J., Karwath, A., Gütlein, M., Maunz, A., Sarimveis, H., Melagraki, G., Afantitis, A., Sopasakis, P., Gallagher, D., Poroikov, V., Filimonov, D., Zakharov, A., Lagunin, A., Gloriozova, T., Novikov, S., Skvortsova, N., Druzhilovsky, D., Chawla, S., Ghosh, I., Ray, S., Patel, H., and Escher, S. (2010) Collaborative development of predictive toxicology applications J. Cheminf. 2, 7 10.1186/1758-2946-2-7
101. Sushko, I., Salmina, E., Potemkin, V. A., Poda, G., and Tetko, I. V. (2012) ToxAlerts: A web server of structural alerts for toxic chemicals and compounds with potential adverse reactions J. Chem. Inf. Model. 52, 2310-2316 10.1021/ci300245q
102. Sushko, I., Novotarskyi, S., Körner, R., Pandey, A. K., Rupp, M., Teetz, W., Brandmaier, S., Abdelaziz, A., Prokopenko, V. V., Tanchuk, V. Y., Todeschini, R., Varnek, A., Marcou, G., Ertl, P., Potemkin, V., Grishina, M., Gasteiger, J., Schwab, C., Baskin, I. I., Palyulin, V. A., Radchenko, E. V., Welsh, W. J., Kholodovych, V., Chekmarev, D., Cherkasov, A., Aires-de-Sousa, J., Zhang, Q. Y., Bender, A., Nigsch, F., Patiny, L., Williams, A., Tkachenko, V., and Tetko, I. V. (2011) Online chemical modeling environment (OCHEM): Web platform for data storage, model development and publishing of chemical information J. Comput.-Aided Mol. Des. 25, 533-554 10.1007/s10822-011-9440-2
103. TOPKAT. http://accelrys.com/products/discovery-studio/admet.html (accessed March 20, 2015).
104. Mombelli, E. (2008) An evaluation of the predictive ability of the QSAR software packages DEREK, HAZARDEXPERT, and TOPKAT to describe chemically-induced skin irritation Altern. Lab. Anim. 36, 15-24
105. Snyder, R. D., Pearl, G. S., Mandakas, G., Choy, W. N., Goodsaid, F., and Rosenblum, I. Y. (2004) Assessment of the sensitivity of the computational programs DEREK, TOPKAT, and MCASE in the prediction of the genotoxicity of pharmaceutical molecules Environ. Mol. Mutagen. 43, 143-158 10.1002/em.20013
106. Cariello, N. F., Wilson, J. D., Britt, B. H., Wedd, D. J., Burlinson, B., and Gombar, V. (2002) Comparison of the computer programs DEREK and TOPKAT to predict bacterial mutagenicity Mutagenesis 17, 321-329 10.1093/mutage/17.4.321
107. Roberts, G., Myatt, G. J., Johnson, W. P., Cross, K. P., and Blower, P. E. (2000) LeadScope: software for exploring large sets of screening data J. Chem. Inf. Model. 40, 1302-1314 10.1021/ci0000631
108. HazardExpertPro. http://www.compudrug.com/hazardexpertpro (accessed March 20, 2015).
109. Marchant, C. A., Briggs, K. A., and Long, A. (2008) In silico tools for sharing data and knowledge on toxicity and metabolism: Derek for Windows, Meteor, and Vitic Toxicol. Mech. Methods 18, 177-187 10.1080/15376510701857320
110. Saiakhov, R. D. and Klopman, G. (2008) MultiCASE Expert Systems and the REACH initiative Toxicol. Mech. Methods 18, 159-175 10.1080/15376510701857460
111. Campillos, M., Kuhn, M., Gavin, A. C., Jensen, L. J., and Bork, P. (2008) Drug target identification using side-effect similarity Science 321, 263-266 10.1126/science.1158140
112. Simmons, D. L., Botting, R. M., and Hla, T. (2004) Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition Pharmacol. Rev. 56, 387-437 10.1124/pr.56.3.3
113. Koutsoukas, A., Simms, B., Kirchmair, J., Bond, P. J., Whitmore, A. V., Zimmer, S., Young, M. P., Jenkins, J. L., Glick, M., Glen, R. C., and Bender, A. (2011) From in silico target prediction to multi-target drug design: current databases, methods, and applications J. Proteomics 74, 2554-2574 10.1016/j.jprot.2011.05.011
114. Schmidt, F., Matter, H., Hessler, G., and Czich, A. (2014) Predictive in silico off-target profiling in drug discovery Future Med. Chem. 6, 295-317 10.4155/fmc.13.202
115. Vidal, D., Garcia-Serna, R., and Mestres, J. (2011) Ligand-based approaches to in silico pharmacology Methods Mol. Biol. 672, 489-502 10.1007/978-1-60761-839-3-19
116. CTlink software, version 2015, Chemotargets SL, Barcelona, Spain. http://www.chemotargets.com (accessed March 20, 2015).
117. Thanacoody, H. K. and Thomas, S. H. (2005) Tricyclic antidepressant poisoning: cardiovascular toxicity Toxicol. Rev. 24, 205-214 10.2165/00139709-200524030-00013
118. Hou, V. Y., Hirshman, C. A., and Emala, C. W. (1998) Neuromuscular relaxants as antagonists for M2 and M3 muscarinic receptors Anesthesiology 88, 744-750 10.1097/00000542-199803000-00026
119. Søndergaard, M. T., Sorensen, A. B., Skov, L. L., Kjaer-Sorensen, K., Bauer, M. C., Nyegaard, M., Linse, S., Oxvig, C., and Overgaard, M. T. (2015) Calmodulin mutations causing catecholaminergic polymorphic ventricular tachycardia confer opposing functional and biophysical molecular changes FEBS J. 282, 803-816 10.1111/febs.13184
120. Ciudin, A., Hernandez, C., and Simó, R. (2012) Update on cardiovascular safety of PPARgamma agonists and relevance to medicinal chemistry and clinical pharmacology Curr. Top. Med. Chem. 12, 585-604 10.2174/156802612799436632
121. Kröger, E., Berkers, M., Carmichael, P. H., Souverein, P., van Marum, R., and Egberts, T. (2012) Use of rivastigmine or galantamine and risk of adverse cardiac events: a database study from the Netherlands Am. J. Geriatr. Pharmacother. 10, 373-380 10.1016/j.amjopharm.2012.11.002
122. Keefe, D. L. (2001) Anthracycline-induced cardiomyopathy Semin. Oncol. 28, 2-7 10.1053/sonc.2001.26431
123. English, B. A., Appalsamy, M., Diedrich, A., Ruggiero, A. M., Lund, D., Wright, J., Keller, N. R., Louderback, K. M., Robertson, D., and Blakely, R. D. (2010) Tachycardia, reduced vagal capacity, and age-dependent ventricular dysfunction arising from diminished expression of the presynaptic choline transporter Am. J. Physiol. Heart. Circ. Physiol. 299, H799-H810 10.1152/ajpheart.00170.2010
124. Zhu, Q. M., Lesnick, J. D., Jasper, J. R., MacLennan, S. J., Dillon, M. P., Eglen, R. M., and Blue, D. R. (1999) Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N α2A-adrenoceptor transgenic mice Br. J. Pharmacol. 126, 1522-1530 10.1038/sj.bjp.0702429
125. Golomb, E., Nyska, A., and Schwalb, H. (2009) Occult cardiotoxicity-toxic effects on cardiac ischemic tolerance Toxicol. Pathol. 37, 572-593 10.1177/0192623309339503
126. Mary-Krause, M., Cotte, L., Simon, A., Partisani, M., and Costagliola, D. (2003) Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men AIDS 17, 2479-2486 10.1097/00002030-200311210-00010
127. Scheiber, J., Chen, B., Milik, M., Sukuru, S. C., Bender, A., Mikhailov, D., Whitebread, S., Hamon, J., Azzaoui, K., Urban, L., Glick, M., Davies, J. W., and Jenkins, J. L. (2009) Gaining insight into off-target mediated effects of drug candidates with a comprehensive systems chemical biology analysis J. Chem. Inf. Model. 49, 308-317 10.1021/ci800344p
128. Duran-Frigola, M. and Aloy, P. (2013) Analysis of chemical and biological features yields mechanistic insights into drug side effects Chem. Biol. 20, 594-603 10.1016/j.chembiol.2013.03.017
129. Duran-Frigola, M., Rossell, D., and Aloy, P. (2014) A chemo-centric view of human health and disease Nat. Commun. 5, 5676 10.1038/ncomms6676
130. Juan-Blanco, T., Duran-Frigola, M., and Aloy, P. (2015) IntSide: a web server for the chemical and biological examination of drug side effects Bioinformatics 31, 612-613 10.1093/bioinformatics/btu688
131. Pauwels, E., Stoven, V., and Yamanishi, Y. (2011) Predicting drug side-effect profiles: a chemical fragment-based approach BMC Bioinf. 12, 169 10.1186/1471-2105-12-169
132. Sturla, S. J., Boobis, A. R., FitzGerald, R. E., Hoeng, J., Kavlock, R. J., Schirmer, K., Whelan, M., Wilks, M. F., and Peitsch, M. C. (2014) Systems toxicology: from basic research to risk assessment Chem. Res. Toxicol. 27, 314-329 10.1021/tx400410s
133. Mizutani, S., Pauwels, E., Stoven, V., Goto, S., and Yamanishi, Y. (2012) Relating drug-protein interaction network with drug side effects Bioinformatics 28, 522-528 10.1093/bioinformatics/bts383
134. Van Kampen, J. M. and Stoessl, A. J. (2000) Dopamine D1A receptor function in a rodent model of tardive dyskinesia Neuroscience 101, 629-635 10.1016/S0306-4522(00)00412-7
135. Kalgutkar, A. S. and Dalvie, D. (2015) Predicting toxicities of reactive metabolite-positive drug candidates Annu. Rev. Pharmacol. Toxicol. 55, 35-54 10.1146/annurev-pharmtox-010814-124720
136. Hert, J., Irwin, J. J., Laggner, C., Keiser, M. J., and Shoichet, B. K. (2009) Quantigying biogenic bias in screening libraries Nat. Chem. Biol. 5, 479-483 10.1038/nchembio.180
137. Pacurariu, A. C., Coloma, P. M., van Haren, A., Genov, G., Sturkenboom, M. C. J. M., and Straus, S. M. J. M. (2014) Drug Saf. 37, 1059-1066 10.1007/s40264-014-0240-1
138. Schuemie, M. J., Coloma, P. M., Straatman, H., Herings, R. M., Trifirò, G., Matthews, J. N., Prieto-Merino, D., Molokhia, M., Pedersen, L., Gini, R., Innocenti, F., Mazzaglia, G., Picelli, G., Scotti, L., van der Lei, J., and Sturkenboom, M. C. (2012) Using electronic health care records for drug safety signal detection: a comparative evaluation of statistical methods Med. Care 50, 890-897 10.1097/MLR.0b013e31825f63bf
139. Obach, R. S., Kalgutkar, A. S., Soglia, J. R., and Zhao, S. X. (2008) Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose Chem. Res. Toxicol. 21, 1814-1822 10.1021/tx800161s
140. Papoian, T., Chiu, H.-J., Elayan, I., Jagadeesh, G., Khan, I., Laniyonu, A. A., Li, C. X., Saulnier, M., Simpson, N., and Yang, B. (2015) Nat. Rev. Drug Discovery 14, 294-296 10.1038/nrd3845-c1
141. Antolín, A. A. and Mestres, J. (2015) Distant polypharmacology among MLP chemical probes ACS Chem. Biol. 10, 395-400 10.1021/cb500393m